Fennec Pharmaceuticals Inc (NASDAQ:FENC) – Stock analysts at Wedbush reduced their Q4 2018 EPS estimates for Fennec Pharmaceuticals in a research report issued on Wednesday, November 14th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($0.17) per share for the quarter, down from their prior estimate of ($0.16). Wedbush currently has a “Outperform” rating and a $16.00 price target on the stock. Wedbush also issued estimates for Fennec Pharmaceuticals’ Q2 2019 earnings at ($0.21) EPS, Q3 2019 earnings at ($0.23) EPS, FY2020 earnings at $0.23 EPS, FY2021 earnings at $0.88 EPS and FY2022 earnings at $2.47 EPS.

Fennec Pharmaceuticals (NASDAQ:FENC) last posted its earnings results on Tuesday, November 13th. The company reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.01.

Several other research firms have also weighed in on FENC. HC Wainwright set a $18.00 target price on shares of Fennec Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, August 14th. Zacks Investment Research downgraded Fennec Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, August 15th. ValuEngine downgraded Fennec Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, September 11th. Goldman Sachs Group assumed coverage on Fennec Pharmaceuticals in a research note on Thursday, October 11th. They set a “buy” rating for the company. Finally, Dawson James assumed coverage on Fennec Pharmaceuticals in a research note on Thursday, October 11th. They set a “buy” rating for the company. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $16.75.

FENC opened at $6.71 on Monday. Fennec Pharmaceuticals has a twelve month low of $5.94 and a twelve month high of $14.99. The stock has a market capitalization of $136.72 million, a PE ratio of -14.28 and a beta of -0.46.

Hedge funds and other institutional investors have recently modified their holdings of the business. United Services Automobile Association grew its holdings in shares of Fennec Pharmaceuticals by 20.7% during the second quarter. United Services Automobile Association now owns 55,348 shares of the company’s stock worth $578,000 after purchasing an additional 9,500 shares during the last quarter. Opaleye Management Inc. grew its holdings in shares of Fennec Pharmaceuticals by 8.2% during the second quarter. Opaleye Management Inc. now owns 945,000 shares of the company’s stock worth $9,865,000 after purchasing an additional 72,000 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Fennec Pharmaceuticals during the second quarter worth about $5,795,000. Schwab Charles Investment Management Inc. bought a new stake in shares of Fennec Pharmaceuticals during the second quarter worth about $221,000. Finally, Bronfman E.L. Rothschild L.P. bought a new stake in shares of Fennec Pharmaceuticals during the second quarter worth about $151,000. 48.69% of the stock is owned by hedge funds and other institutional investors.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.

Featured Story: Fundamental Analysis – How It Helps Investors

Earnings History and Estimates for Fennec Pharmaceuticals (NASDAQ:FENC)

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.